<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/42/254c–2" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/42/254c–2/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/42/254c–2/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_254c_2"><akn:num>254c–2</akn:num><akn:heading>Special diabetes programs for type I diabetes</akn:heading><akn:content><akn:p>§ 254c–2. Special diabetes programs for type I diabetes(a) In generalThe Secretary, directly or through grants, shall provide for research into the prevention and cure of Type 11 So in original. Probably should not be capitalized. I diabetes.


(b) Funding(1) Transferred fundsNotwithstanding section 1397dd(a) of this title, from the amounts appropriated in such section for each of fiscal years 1998 through 2002, $30,000,000 is hereby transferred and made available in such fiscal year for grants under this section.


(2) AppropriationsFor the purpose of making grants under this section, there is appropriated, out of any funds in the Treasury not otherwise appropriated—(A) $70,000,000 for each of fiscal years 2001 and 2002 (which shall be combined with amounts transferred under paragraph (1) for each such fiscal years);

(B) $100,000,000 for fiscal year 2003;

(C) $150,000,000 for each of fiscal years 2004 through 2017;

(D) $150,000,000 for each of fiscal years 2018 through 2023, to remain available until expended;

(E) $19,726,027 for the period beginning on October 1, 2023, and ending on November 17, 2023, $25,890,411 for the period beginning on November 18, 2023, and ending on January 19, 2024, $20,136,986 for the period beginning on January 20, 2024, and ending on March 8, 2024, and $130,000,000 for the period beginning on March 9, 2024, and ending on December 31, 2024, to remain available until expended;

(F) $39,261,745 for the period beginning on January 1, 2025, and ending on March 31, 2025, to remain available until expended;

(G) $79,832,215 for the period beginning on April 1, 2025, and ending on September 30, 2025, to remain available until expended; and

(H) $53,145,205 for the period beginning on October 1, 2025, and ending on January 30, 2026, to remain available until expended.



(July 1, 1944, ch. 373, title III, § 330B, as added Pub. L. 105–33, title IV, § 4921, Aug. 5, 1997, 111 Stat. 574; amended Pub. L. 105–34, title XVI, § 1604(f)(1)(B), (C), A</akn:p></akn:content><akn:subsection eId="subsec_254c_2_a"><akn:num>(a)</akn:num><akn:heading>In general</akn:heading><akn:content><akn:p>(a) In general The Secretary, directly or through grants, shall provide for research into the prevention and cure of Type 11 So in original. Probably should not be capitalized. I diabetes.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_254c_2_b"><akn:num>(b)</akn:num><akn:heading>Funding</akn:heading><akn:content><akn:p>(b) Funding</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>